Abstract: An apparatus (1) provided to connect at least one device (2) to a power distribution system (3), said apparatus (1) comprising a human machine interface, HMI, (4) having elements to interact with the apparatus (1), wherein the human machine interface elements (11,12) are adapted to display and/or to adjust setting values of operation parameters of the at least one connected device (2), wherein access to one or more human machine interface elements is restricted by at least one access restriction mechanism of said apparatus (1) to enhance the operation security of the at least one device (2) connected via said apparatus (1) to said power distribution system (3) and/or to enhance the operation security of the apparatus (1) and/or of the power distribution system (3).

Abstract: An apparatus for switching and/or protection of a load connected to said apparatus, said apparatus (1) comprising: a power switch (5) through which the connected load receives an electrical current; a sensor component (4) connected in series with said power switch (5) and adapted to generate directly an electrical voltage drop corresponding to a current rise speed of the electrical current flowing via the sensor component (4) and via the power switch (5) to said load; and a driver circuit (6) adapted to detect an occurring overcurrent depending on a voltage drop generated by said sensor component (4) with or without a voltage drop along the power switch (5) and to switch off said power switch (5) upon detection of an overcurrent within a switch-off period to protect said power switch (5) and said load.

Abstract: The present invention generally relates to the field of immunomodulation and provides various costimulatory polypeptides comprising at least one 4-1BBL ectodomain comprising a (core) minimal TNF Homology Domain. Further provided are vectors and oncolytic viruses expressing the 4-1BBL ectodomain and methods for producing the same. Additionally provided are 5 methods and uses for obtaining and optionally purifying the inherently oligomerizing 4-1BBL ectodomain polypeptides and associated oncolytic viruses for highly targeted cancer treatment, including the treatment of tumors. Finally, there are provided kits and uses of the polypeptides and vectors as disclosed.

Abstract: The present invention relates to a pharmaceutical composition comprising complement split product C4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The C4d to be used may be a multimer. Accordingly, also C4d multimers and their use in medicine, like the treatment of inflammatory conditions, is provided. Furthermore, the present invention provides a protein complex comprising C4d interacting with its ILT4 receptor. This protein complex may be used in screening methods Also antibodies specifically binding to the C4d multimer or the C4d/ILT4-protein complex are subject of the present invention.

Abstract: The present invention relates to a pharmaceutical composition comprising complement split product C4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The C4d to be used may be a multimer. Accordingly, also C4d multimers and their use in medicine, like the treatment of inflammatory conditions, is provided. Furthermore, the present invention provides a protein complex comprising C4d interacting with its ILT4 receptor. This protein complex may be used in screening methods Also antibodies specifically binding to the C4d multimer or the C4d/ILT4-protein complex are subject of the present invention.

Abstract: The present invention relates to a pharmaceutical composition comprising complement split product C4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The C4d to be used may be a multimer. Accordingly, also C4d multimers and their use in medicine, like the treatment of inflammatory conditions, is provided. Furthermore, the present invention provides a protein complex comprising C4d interacting with its ILT4 receptor. This protein complex may be used in screening methods Also antibodies specifically binding to the C4d multimer or the C4d/ILT4-protein complex are subject of the present invention.

Abstract: The present invention relates to a pharmaceutical composition comprising complement split product C4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The C4d to be used may be a multimer. Accordingly, also C4d multimers and their use in medicine, like the treatment of inflammatory conditions, is provided. Furthermore, the present invention provides a protein complex comprising C4d interacting with its ILT4 receptor. This protein complex may be used in screening methodsAlso antibodies specifically binding to the C4d multimer or the C4d/ILT4-protein complex are subject of the present invention.

Abstract: The present invention relates to group 2 allergen specific IgE-Fabs and whole Ig molecules as well as use thereof. More precisely, the present invention relates to grass pollen specific IgE-Fabs (Phl p2) and reagents, kits and vaccines comprising these. The invention also relates to use of group 2 specific IgE-Fabs and whole Ig for, inter alia, diagnosis, therapy and prevention of type I allergy.

Abstract: The present invention relates to group 2 allergen specific IgE-Fabs and whole Ig molecules as well as use thereof. More precisely, the present invention relates to grass pollen specific IgE-Fabs (Phl p2) and reagents, kits and vaccines comprising these. The invention also relates to use of group 2 specific IgE-Fabs and whole Ig for, inter alia, diagnosis, therapy and prevention of type I allergy.

Abstract: A method for inhibiting, diminishing, preventing or treating pathogenic infection of cells comprising expressing a recombinant antibody protein fused to an intracellular anchor means, wherein said antibody is specific for a surface receptor of said cells necessary for pathogenic infection, wherein said antibody is suitably selected from CCR5 and CXCR4 specific antibodies. A recombinant antibody protein fused to an intracellular anchor means which is specific for a surface receptor necessary for pathogenic infection, but suitably elected from CCR5 and CXCR4 specific antibodies and humanized antibodies therefrom. A recombinant antibody that immunoreacts with CCR5 or CXCR4 surface receptor. Peptides comprising at least YTSF or YTSQ sequence for use in a vaccine or an immunogenic composition intended to control, prevent, diminish or treat HIV infections. An antiidiotypic antibody mimicking CCR5 or CXCR4 epitopes raised from anti-CCR5 and anti-CXCR4 antibodies.